The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial

By sjmartinez • December 2, 2024

Secord AA, Lewin SN, Murphy CG, Cecere SC, Barquín A, Gálvez-Montosa F, Mathews CA, Konecny GE, Ray-Coquard I, Oaknin A, Pérez MJR, Bonaventura A, Diver EJ, Ayuk SA, Wang Y, Corr BR, Salutari V. The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial. Ann Oncol. 2024 Nov 29:S0923-7534(24)04948-2. doi: 10.1016/j.annonc.2024.11.011. Epub ahead of print. PMID: 39617145.

Tags: antibody-drug conjugate, Folate receptor alpha, heavily pretreated (max 6), Infectious Diseases, Mirvetuximab soravtansine, Platinum-sensitive ovarian cancer, Publications

Reducing excess antibiotic use with rapid tests to distinguish bacterial from nonbacterial causes of respiratory symptoms

Allan-Blitz LT, Klausner JD. Reducing excess antibiotic use with rapid tests to distinguish bacterial from nonbacterial causes of respiratory symptoms. Antimicrob Steward Healthc Epidemiol. 2026[...]

Resistance-guided therapy and integration of novel therapeutics are key to facilitating antimicrobial stewardship for sexually transmitted infections

Allan-Blitz LT, Klausner JD. Resistance-guided therapy and integration of novel therapeutics are key to facilitating antimicrobial stewardship for sexually transmitted infections. Antimicrob Steward Healthc Epidemiol.[...]

Defining and validating an HPV vaccination motivation score in Kenya and Malawi: A tool for use in low- and middle-income countries

Moucheraud C, Li G, Ochieng E, Golub G, Phiri K, Chibaka S, Ganda G, Phiri S, Hyman S, Hoffman RM, Szilagyi PG, Dahlen A. Defining[...]